Moody Aldrich Partners LLC Purchases Shares of 24,657 Novavax, Inc. (NASDAQ:NVAX)

Moody Aldrich Partners LLC purchased a new stake in Novavax, Inc. (NASDAQ:NVAX) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 24,657 shares of the biopharmaceutical company’s stock, valued at approximately $2,055,000.

Other hedge funds also recently bought and sold shares of the company. Global Retirement Partners LLC bought a new position in Novavax in the second quarter valued at approximately $25,000. Central Bank & Trust Co. bought a new position in Novavax in the second quarter valued at approximately $33,000. Nisa Investment Advisors LLC boosted its stake in shares of Novavax by 19.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 455 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 75 shares during the period. Evolution Wealth Advisors LLC bought a new position in shares of Novavax during the 2nd quarter worth approximately $50,000. Finally, Optimum Investment Advisors bought a new position in shares of Novavax during the 2nd quarter worth approximately $167,000. Hedge funds and other institutional investors own 22.64% of the company’s stock.

Several research analysts have recently commented on NVAX shares. Zacks Investment Research downgraded Novavax from a “buy” rating to a “hold” rating in a research note on Wednesday, July 1st. HC Wainwright lifted their target price on Novavax from $101.00 to $132.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. BidaskClub upgraded Novavax from a “buy” rating to a “strong-buy” rating in a research note on Friday, May 15th. JPMorgan Chase & Co. upgraded Novavax from an “underweight” rating to a “neutral” rating and set a $46.00 target price for the company in a research note on Friday, June 5th. Finally, LADENBURG THALM/SH SH reiterated a “neutral” rating and set a $105.00 target price (up from $50.00) on shares of Novavax in a research note on Wednesday, July 8th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $87.19.

NASDAQ:NVAX traded down $3.52 during mid-day trading on Friday, hitting $143.10. 4,232,099 shares of the stock were exchanged, compared to its average volume of 7,386,336. The stock has a market capitalization of $8.29 billion, a price-to-earnings ratio of -34.57 and a beta of 1.50. The firm’s 50-day simple moving average is $95.24 and its 200 day simple moving average is $37.96. Novavax, Inc. has a fifty-two week low of $3.54 and a fifty-two week high of $154.70.

Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.67) by $0.09. The firm had revenue of $3.38 million for the quarter, compared to analyst estimates of $3.50 million. During the same period in the previous year, the business posted ($2.20) earnings per share. As a group, equities analysts anticipate that Novavax, Inc. will post 5.45 EPS for the current fiscal year.

In related news, Director James F. Young acquired 1,500 shares of the company’s stock in a transaction on Wednesday, June 3rd. The stock was purchased at an average cost of $48.83 per share, with a total value of $73,245.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Gregory M. Glenn sold 16,749 shares of Novavax stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $59.53, for a total value of $997,067.97. Following the completion of the transaction, the insider now directly owns 18,588 shares of the company’s stock, valued at $1,106,543.64. The disclosure for this sale can be found here. 3.30% of the stock is owned by insiders.

Novavax Company Profile

Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.

Recommended Story: How to calculate the annual rate of depreciation

Want to see what other hedge funds are holding NVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novavax, Inc. (NASDAQ:NVAX).

Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News